The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The role of stromal cells and the tumour microenvironment in general in modulating tumour sensitivity is increasingly becoming a key consideration for the development of active anticancer therapeutics. Here, we discuss how these tumour-stromal interactions affect tumour cell signalling, survival, proliferation and drug sensitivity. Particular emphasis is placed on the ability of stromal cells to confer - to tumour cells - resistance or sensitization to different classes of therapeutics, depending on the specific microenvironmental context. The mechanistic understanding of these microenvironmental interactions can influence the evaluation and selection of candidate agents for various cancers, in both the primary site as well as the metastatic setting. Progress in in vitro screening platforms as well as orthotopic and 'orthometastatic' xenograft mouse models has enabled comprehensive characterization of the impact of the tumour microenvironment on therapeutic efficacy. These recent advances can hopefully bridge the gap between preclinical studies and clinical trials of anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“Hence, tumor-stromal interactions, the composition of the TME and tumor immune status all contribute to determining tumor growth, metastasis, angiogenesis and therapy resistance (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021), thereby critically influencing the clinical outcome of cancer patients.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“In addition, many studies have highlighted the critical importance of the microenvironment for promoting or suppressing tumor growth, invasion, metastasis, and response to therapy (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“The non‐malignant cells and matrixcomponents which make up the TME have been shown to playa role in tumor cell survival, proliferation,andtreatment resistance (48).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [48]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Cited by
Items 301–400 of 491
Li, J., Liu, J., Xia, W., Yang, H., Sha, W., & Chen, H. H. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231221856 · Cited by 15
“6 On the other hand, cancer cell lines would gradually lose the tumor genetic and intratumoral heterogeneity after multiple passages, which means that cancer cell lines cannot fully maintain the molecular and histological features of the original tumor tissue.”
BackgroundCx43 in Neural Progenitors Promotes Glioma Invasion in a 3D Culture System
Khosla, K., Naus, C. C. G., & Sin, W. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155216 · Cited by 13
“The tissue environment that envelops the glioma cells not only affects the dissemination of cancer cells, but it also influences the susceptibility of cancer cells to therapeutic intervention [24].”
BackgroundMicrofluidic Reconstitution of Tumor Microenvironment for Nanomedical Applications
Oh, H. J., Kim, J., Kim, H., Choi, N., & Chung, S. H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002122 · Cited by 13
Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment
Piñeiro-Pérez, R., Abal, M., & Muinelo‐Romay, L. (2022) · Cancers · doi:10.3390/cancers14061405 · Cited by 13
“These PDO models are important tools to better capture the tumour microenvironment interactions that condition therapy response, as happens in the case of immunotherapy [94].”
MethodParker, S. J., Raedschelders, K., & Eyk, J. E. V. (2014) · PROTEOMICS · doi:10.1002/pmic.201400448 · Cited by 14
“One explanation that partially accounts for these metrics is that preclinical research studies that identify candidate drugs inadequately capture the biological complexity and context in which a therapeutic is meant to operate [3, 4].”
BackgroundLee, S., NAM, J. K., Park, J. K., Lee, J., Min, D. S., & Kuh, H. (2014) · Oncology Reports · doi:10.3892/or.2014.3337 · Cited by 15
Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells
Kučerová, L., Durinikova, E., Toro, L., Cihova, M., Miklikova, S., Poturnajova, M., Kozovská, Z., & Matúšková, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.016 · Cited by 13
“MSCs together with other components of the tumor microenvironment protect tumor cells from the effect of chemo-therapeutic agents [39].”
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Understanding therapeutic tolerance through a mathematical model of drug-induced resistance
Gevertz, J. L., Greene, J. M., Prosperi, S., Comandante-Lou, N., & Sontag, E. D. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00511-3 · Cited by 14
“Asaresult,thesametherapeuticdesignmay resultindifferentoutcomesdependingonthe(dominant)modeofresis-tance.”
Algarín, E. M., Quwaider, D., Campos-Laborie, F. J., Díaz-Tejedor, A., Mogollón, P., Vuelta, E., Martín-Sánchez, M., San‐Segundo, L., González-Méndez, L., Gutierrez, N. C., et al. (2021) · Cells · doi:10.3390/cells10030559 · Cited by 13
“In fact, after interaction with BMMSCs, multiple transcripts belonging to a great diversity of molecular networks (oncogenic kinases, cytokines, chemokines and chemokine receptors, oncogenic transcription factors, cell cycle regulators, and anti-apoptotic family members, among others) are differentially expressed in M…”
BackgroundContact-dependent transfer of TiO2nanoparticles between mammalian cells
Schoelermann, J., Burtey, A., Allouni, Z. E., Gerdes, H., & Cimpan, M. R. (2015) · Nanotoxicology · doi:10.3109/17435390.2015.1048322 · Cited by 12
“Exploiting NP transfer in nanomedicine seems particularly tempting considering the importance of cell-to-cell communication in various disorders, such as for example cancer (Hamada et al., 2013; Mcmillin et al., 2013) or neurodegenerative diseases (Garden & La Spada, 2012).”
BackgroundThakur, S. S., Nabbi, A., Klimowicz, A. C., & Riabowol, K. T. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0434-x · Cited by 15
“As stroma derived factors promote initiation, growth and progression of tumor cells, they can also determine the therapeutic outcome in patients as they can act as barriers to therapy [15].”
BackgroundModeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer
Falcetta, F., Bizzaro, F., D’Agostini, E., Bani, M. R., Giavazzi, R., & Ubezio, P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1099 · Cited by 12
Xia, Q., Tang, Y., Li, W., Liang, T., Zhou, Y., Liu, J., & Liu, F. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s404486 · Cited by 12
“Even if the drugs are successfully delivered into a solid tumor, their effectiveness is limited through tumor exploitation of counter-regulatory mechanisms.(3,5) The existence of an immunosuppressed TME has become a major therapy hurdle for solid tumors.”
BackgroundWong, S. W., Lenzini, S. B., & Shin, J. (2018) · APL Bioengineering · doi:10.1063/1.5025689 · Cited by 14
Microscale Gene Expression Analysis of Tumor-Associated Macrophages
Attri, K. S., Mehla, K., Shukla, S. K., & Singh, P. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-20820-4 · Cited by 12
Cancer 3D Models for Metallodrug Preclinical Testing
Engrácia, D. M., Pinto, C. I. G., & Mendes, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511915 · Cited by 12
“The complexity of the tumor’s microenvironment and the interactions established with cancer cells are the main reasons 2D models fail to accurately replicate the in vivo tissue [29].”
BackgroundAdvances in the molecular mechanisms underlying progestin resistance in endometrial cancer
Liu, J., Zhou, J., Wang, Y., Xue, F., Chen, X., Chen, G., & Wang, J. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.07.008 · Cited by 12
“Several studies have demonstrated successful efforts to derive organoids from malignant endometrium [ 176,177 ].”
Exploring tumor organoids for cancer treatment
Jin, H., Yang, Q., Yang, J., Wang, F., Feng, J., Lei, L., & Dai, M. (2024) · APL Materials · doi:10.1063/5.0216185 · Cited by 11
Role of vascular endothelium and exosomes in cancer progression and therapy (Review)
Dai, Y., Yao, Y., He, Y., & Hu, X. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5712 · Cited by 11
Evaluation of the Effect of Fibroblasts on Melanoma Metastasis Using a Biomimetic Co-Culture Model
Wu, M., Yu, E., Ye, K., Huang, Y., Ren, T., Guo, M., Yin, J., Xu, K., & Wei, P. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01186 · Cited by 13
Farahmand, Y., Tehrany, P. M., Nazari, A., Nava, Z. H., Alsaffar, M. F., Yazdani, O., Adili, A., Esbati, R., & Ghafouri, K. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154465 · Cited by 11
Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice
Westwood, J. A., Hunnam, T. C. U. P., Pegram, H. J., Hicks, R. J., Darcy, P. K., & Kershaw, M. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095847 · Cited by 11
“Therefore recommendations have been made to test therapies in orthotopic models [6,7,29,30,32–34] which are thought to be Table 2.”
BackgroundCASTIN: a system for comprehensive analysis of cancer-stromal interactome
Komura, D., Isagawa, T., Kishi, K., Suzuki, R. H., Sato, R., Tanaka, M. H., Katoh, H., Yamamoto, S., Tatsuno, K., Fukayama, M., et al. (2016) · BMC Genomics · doi:10.1186/s12864-016-3207-z · Cited by 12
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
Jakša, R., Karolová, J., Svatoň, M., Kazantsev, D., Grajciarová, M., Pokorná, E., Tonar, Z., Klánová, M., Winkowska, L., Maláriková, D., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00784-w · Cited by 12
Garcia, N., Ulin, M., Ali, M. K., Al-Hendy, A. A., Carvalho, K. C., & Yang, Q. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00731-y · Cited by 11
Lyu, S., Meshesha, S. M., & Hong, C.-E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010366 · Cited by 12
“These resistance mechanisms include enhanced drug efflux through P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) [45], increased DNA repair capacity [46], altered apoptotic signaling [47], and a modified tumor microenvironment [48].”
Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma
Huang, C. L., Li, Y., Zhang, F., Zhang, C., & Ding, Z. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002294 · Cited by 14
“This section focuses on other factors in the TME, including the role of hepatitis viruses, which are closely associated with HCC [ 1 , 82–86 ] .”
Tao, Z., Han, J., Xu, J., Zhao, E., Wang, M., Wang, Z., Lin, X., Xiao, X., Hong, J., Chen, H., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102039 · Cited by 16
Engineering human endometrial model systems in reproductive health and disease
Wang, Y., Guo, Y., Yang, Y., Ma, X., & Qin, J. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00047-5 · Cited by 12
“However, organoid models have not fully captured tumor-matrix interactions that in fl uence drug sensitivity and resistance, which are important for immune-oncology research 128 .”
Lawasut, P., Groen, R. W. J., Dhimolea, E., Richardson, P. G. G., Anderson, K. C., & Mitsiades, C. S. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.010 · Cited by 13
Self-citationSasaki, N., Bos, C., Escoffre, J., Storm, G., & MOONEN, C. T. W. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.039 · Cited by 11
“Thirdly, the ECM in cancer stroma has a great impact on cancer chemotherapy (McMillin et al., 2013), and a tissue mimicking system should preferably also allow the presence of an ECM.”
Li, B., Yang, L., Wang, X., Yan, Z., Liu, H., Liu, G., & Liu, S. (2015) · Europe PMC (PubMed Central) · Cited by 11
Kang, A.-R., Cho, J., Lee, N.-G., Song, J. Y., Hwang, S., Lee, D.-H., Um, H., & Park, J. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134584 · Cited by 13
“Recently, several therapy-induced TME responses have received considerable attention, owing to their potential to enhance therapeutic efficiency or evoke resistance [32,33].”
BackgroundDie-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance
Ogden, A., Rida, P. C. G., Reid, M. D., Küçük, Ö., & Aneja, R. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1016425 · Cited by 9
“Solid tumors, by contrast, are highly heterogeneous, 3D structures that associate with stromal cells in a complex, potentially noxious microenvironment [29].”
BackgroundPizzimenti, S. (2014) · Journal of Pediatric Oncology · doi:10.14205/2309-3021.2014.02.01.5 · Cited by 11
Aldaghi, S. A., & Jalal, R. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00335 · Cited by 10
Systemic Mobilization of Breast Cancer Resistance Protein in Response to Oncogenic Stress
Szczygieł, M., Markiewicz, M., Szafraniec, M. J., Hojda, A., Fiedor, L., & Urbanska, K. (2022) · Cancers · doi:10.3390/cancers14020313 · Cited by 9
Advancing Tumor Microenvironment Research by Combining Organs-on-Chips and Biosensors
Calejo, I., Heinrich, M. A., Zambito, G., Mezzanotte, L., Prakash, J., & Teixeira, L. M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-04039-9_7 · Cited by 9
Preclinical tumor mouse models for studying esophageal cancer
Mahmoudian, R. A., Farshchian, M., Golyan, F. F., Mahmoudian, P., Alasti, A., Moghimi, V., Maftooh, M., Khazaei, M., Hassanian, S. M., Ferns, G. A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104068 · Cited by 9
Lee, H. W., Lee, K., Kim, D. G., Yang, H., & Nam, D. (2016) · PubMed · doi:10.14670/hh-11-695 · Cited by 8
“The cellular components of the tumor stromal microenvironment as well as soluble cytokines, chemokines, cell matrix components, and adhesion proteins not only influence the natural history of tumor proliferation, angiogenesis, and invasion, but are also specifically capable of altering the response of tumors to therap…”
BackgroundSalle, H., Pocard, M. D., Lehmann‐Che, J., Bourthoumieu, S., Labrousse, F., Pimpie, C., Lemnos, L., Guichard, J., Froelich, S. C., & Adle‐Biassette, H. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz121 · Cited by 9
5-Fluorouracil Treatment of CT26 Colon Cancer Is Compromised by Combined Therapy with IMMODIN
Demečková, V., Mudroňová, D., Gancarčíková, S., Kubatka, P., Kajo, K., Kassayová, M., Bojková, B., Adamkov, M., & Solár, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126374 · Cited by 8
“Moreover, the tumour microenvironment and immune reaction, including different cytokines, have an important role in the regulation and modulation of bodily response to 5-FU therapy [28,29].”
BackgroundThe potential impact of mouse model selection in preclinical evaluation of cancer immunotherapy
Westwood, J. A., Darcy, P. K., & Kershaw, M. H. (2014) · OncoImmunology · doi:10.4161/21624011.2014.946361 · Cited by 8
“There are now several published articles which attest that preclinical testing of anticancer therapies does not have a good record of predicting success once moved to the clinic.(2) One of the problems attested to is the use of SC models, which are considered a poor surrogate model for metastatic human cancers.”
BackgroundFu, S., Dong, L., Sun, W., Xu, Y., Gao, L., & Miao, Y. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.849723 · Cited by 11
Jiang, W., Mautner, V., Friedrich, R. E., & Kluwe, L. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.172 · Cited by 8
Assessing Specificity of Anticancer Drugs In Vitro
Kluwe, L. (2016) · Journal of Visualized Experiments · doi:10.3791/53752 · Cited by 8
Paindelli, C., Parietti, V., Barrios, S., Shepherd, P. D. A., Pan, T., Wang, W., Satcher, R. L., Logothetis, C. J., Navone, N. M., Campbell, M. T., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.02.025 · Cited by 7
Controlling Cell Organization in 3D Coculture Spheroids Using DNA Interactions
Saemundsson, S. A., Ganguly, S., Curry, S. D., Goodwin, A. P., & Cha, J. N. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00546 · Cited by 8
Li, X., Wang, Z., Man, X., Dai, X., Zhou, Q., & Zhang, S. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.02.022 · Cited by 7
“Nonetheless, 2D culture remains a prevalent tool for preliminary studies due to its simplicity, low cost, and high-throughput screening capabilities [12].”
A novel humanized immune stroma PDX cancer model for therapeutic studies
Yang, D., Beddows, I., Tang, H., Bai, S., Cascio, S., McGonigal, S. C., Johnson, B. K., Powers, J. J., Acharya, R., Bao, R., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04349-4 · Cited by 8
Vlieghere, E. D., de Vijver, K. K. V., Blondeel, E., Carpentier, N., Ghobeira, R., Pauwels, J., Riemann, S., Minsart, M., Fieuws, C., Mestach, J., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00441-3 · Cited by 8
“In addition, there is an increased awareness that elements from the tumor microenvironment (TME), such as cancer-associated fibroblast (CAF), contribute to therapy response [2– 4].”
BackgroundAgrawal, K., Das, V., Kudlová, N., Gurský, J., Džubák, P., & Hajdúch, M. (2018) · Stem Cells International · doi:10.1155/2018/6013728 · Cited by 7
Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy
Gruessner, C., Wiestner, A., & Sun, C. (2025) · Leukemia & Lymphoma · doi:10.1080/10428194.2025.2466101 · Cited by 6
“…cells and matrix components which make up the tMe have been shown to play a role in tumor cell survival, proliferation, and treatment resistance [47]. integrins are adhesion molecules that function as anchors in retaining tumor cells in supportive tissues and facilitate tumor spread. within the…”
Liang, Y.-L., Zhong, C., Wu, J., Lin, Z.-J., Lin, Z., Yi, T.-J., Chen, Z., Jin, H.-L., Yu, J.-D., Li, G., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03654-z · Cited by 7
“The mechanism of gemcitabine resistance involves abnormal nucleoside transport, changes in metabolic enzymes, DNA damage repair, tumor microenvironment, and anti-apoptotic response [12 – 15].”
Hu, Q., Rix, L. L. R., Desai, B., Miroshnychenko, D., Li, X., Welsh, E. A., Fang, B., Wright, G. M., Chaudhary, N., Kroeger, J. L., et al. (2025) · Science Signaling · doi:10.1126/scisignal.ads7662 · Cited by 6
Karancsi, Z., Hagenaars, S. C., Németh, K., Mesker, W. E., Tõkés, A., & Kulka, J. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03555-0 · Cited by 6
Fang, L., Liu, Y., Zhang, Y., Pan, Z., Zhong, L., Jiang, L., Wang, J., Zheng, X., Chen, L.-Y., Huang, P. C., et al. (2021) · Journal of Cancer · doi:10.7150/jca.50897 · Cited by 6
“The phenotypic discrepancies between preclinical models and patients is a challenge in basic cancer studies and in efforts to discover and develop antineoplastic agents [18-21].”
Langella, A., Gadau, S. D., Serra, E., Bebbere, D., & Ledda, S. (2022) · Biology · doi:10.3390/biology11040492 · Cited by 6
“One peculiarity of GBM, which often underlies the ineffectiveness of therapeutic treatments, is the ability of cancer cells to invade surrounding brain tissues, thus emphasizing the key role of the interaction between cellular elements and the extracellular matrix [2,3].”
BackgroundReport on the use of non‐clinical studies in the regulatory evaluation of oncology drugs
Hayakawa, Y., Kawada, M., Nishikawa, H., Ochiya, T., Saya, H., Seimiya, H., Yao, R., Hayashi, M., Kai, C., Matsuda, A., et al. (2016) · Cancer Science · doi:10.1111/cas.12857 · Cited by 7
Influence of wound fluid on chemotherapy sensitivity in primary breast cancer cells
Zhang, Y., Yan, D., Zhang, H., Ou, X., Zhao, Z., Wang, D., & Liu, C. (2016) · Oncotarget · doi:10.18632/oncotarget.11345 · Cited by 6
Overexpression of PITPNM3 promotes hepatocellular carcinoma cell metastasis
He, C., Su, S., Chen, F., Huang, D., Zheng, F., Huang, W., Chen, J., Cui, X., Liu, Q., Song, E., et al. (2014) · Chinese Science Bulletin · doi:10.1007/s11434-014-0183-z · Cited by 6
Humanized Mouse and Rat PDX Cancer Models
Noto, F. K., & Jamling, T. Y. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_4 · Cited by 8
“It is hypothesized that one of the reasons human cancer xenografts in the rodent do not faithfully predict therapeutic efficacy is because the immune component of the stroma is derived from the host, and not of human origin [36, 37].”
BackgroundConnexin 43 inhibitors reduce cell viability in glioblastoma and astrocyte co-culture systems
Genc, A., Uzunkaya, B., Yengin, G. I., Tecimel, D., Dalan, A. B., & Bayrak, Ö. F. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10902-8 · Cited by 5
“Cellular communication supports cancer cell survival, promotes invasion, and metastatic dissemination, and mediates drug response [21, 22].”
Immune Cells: Critical Players in Drug Resistance
Khan, S. U., Jan, S., Fatima, K., & Malik, F. A. (2024) · Springer eBooks · doi:10.1007/978-981-97-1666-1_4 · Cited by 5
Niu, X., Tian, W., Ke, Y., Li, Y., & Zhang, X. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03930-8 · Cited by 5
“The initiation and progression of tumor metastasis involve a complex interplay between multiple cells and factors, influenced by both tumor cells and the surrounding tumor microenvironment [11].”
Anand, K., Chandrasekaran, B., Gupta, G., Dureja, H., Singh, S. K., Gulati, M., Chellappan, D. K., Balasubramanian, B., Femeela, I., Arumugam, V. A., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85503-7.00037-7 · Cited by 5
Tang, T., Zhang, P., Zhang, Q., Man, X., & Xu, Y. (2024) · Biofabrication · doi:10.1088/1758-5090/ad647e · Cited by 6
“These tumor-stromal interactions, which involve tumor cell proliferation and invasion, tissue vascularization, and drug resistance, are become increasingly important in oncology research [7].”
Shen, J., & Zhu, W. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4810 · Cited by 5
Küçükköse, E., Wensink, G. E., Roelse, C. M., van Schelven, S. J., Raats, D., Boj, S. F., Koopman, M., Laoukili, J., Roodhart, J. M. L., & Kranenburg, O. (2021) · Cancers · doi:10.3390/cancers13215434 · Cited by 5
“An alternative explanation could be that the distinct microenvironments of pMMR and dMMR CRC could influence treatment response [23].”
BackgroundKluwe, L., Jiang, W., Alster, I., & Hanken, H. (2015) · Biomedical Papers · doi:10.5507/bp.2015.057 · Cited by 5
Shirbhate, E., Singh, V. P., Kore, R., Vishwakarma, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266284527240118041129 · Cited by 4
Delgado-SanMartin, J. A., Hare, J. I., Davies, E. J., & Yates, J. W. T. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0461-1 · Cited by 4
“Recently, it has been demonstrated that the tumour microenvironment can affect tumour pathophysiology [3], therapeutic sensitivity, and response [4, 5].”
BackgroundTransición epitelio – mesenquima y cáncer.
Arvelo, F. A., & Sojo, F. J. (2023) · Investigación Clínica · doi:10.54817/ic.v64n3a10 · Cited by 5
Molecular and Cellular Basis of Chemoresistance in Ovarian Cancer
Asare-Werehene, M., Shieh, D., Song, Y. S., & Tsang, B. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813209-8.00035-2 · Cited by 4
Bioprinting of Biomimetic Tissue Models for Disease Modeling and Drug Screening
Tang, M., Berry, D. B., Miller, K. L., Ma, X., & Chen, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824552-1.00002-5 · Cited by 6
Quadri, M., Iuliano, M., Rosa, P., Mangino, G., & Palazzo, E. (2025) · Life · doi:10.3390/life15081170 · Cited by 4
Cox, M. C., Mendes, R. G. P. R., Halwachs, K. N., Domenici, G., Brito, C., & Boghaert, E. R. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2216016 · Cited by 3
“the phenotype of CAFs, ECs, and immune cells are often changed in the TME by epigenetic modification) can also alter the response of tumors to therapeutics [100,101].”
BackgroundInvestigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma
Liu, J., Li, W., Lü, R., Xu, J., Jiang, C., DUAN, J., Zhang, L., Wang, G., & Chen, J. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.043575 · Cited by 3
Interactions between cancer and stroma mediated by extracellular vesicles
Najafzadeh, M., Sajjadi, S. M., Kharazi, S., Karimifard, F., Safarpour, H., & Kharazinejad, E. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00582-7 · Cited by 3
“Interactions between stromal cells with tumor cells are important in tumor biology, directing cell signaling, proliferation, survival, and drug sensitivity [3].”
BackgroundYang, E., Ji, L., Zhang, X., Jing, S., Li, P., Wang, H., Zhang, L., Zhang, Y., Yang, L., Tian, J., et al. (2024) · Stem Cells International · doi:10.1155/sci/6064671 · Cited by 3
Tissue Regeneration with Hydrogel Encapsulation: A Review of Developments in Plants and Animals
Krishnamoorthy, S., Schwartz, M. F., den Broeck, L. V., Hunt, A., Horn, T., & Sozzani, R. (2021) · BioDesign Research · doi:10.34133/2021/9890319 · Cited by 4
Witkowski, J., Polak, S., Pawelec, D., & Rogulski, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032239 · Cited by 3
Zhang, C., Zhang, X., Yang, S., & Chen, X.-H. (2017) · Oncology Letters · doi:10.3892/ol.2017.5686 · Cited by 3
Synthesis and biological evaluation of N-Alkylamide derivatives as anti-tumor agents
Jiang, K., Xing, Y., Quan, Q., Sun, Q., Tian, J., Liu, C., Song, X., Wang, X., & Liu, Y. (2020) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2020.09.004 · Cited by 3
Gevertz, J. L., Greene, J. M., & Sontag, E. D. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.27.889444 · Cited by 3
“For example, the upregulation of drug efflux transporters, enhanced DNA repair mechanisms, modification of drug targets, stem cells, irregular tumor vasculature, environmental pH, immune cell infiltration and activation, and hypoxia have all been identified as mechanisms which may inhibit treatment efficacy [7, 8, 6,…”
BackgroundA20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β
Luo, F., Yang, T., Cao, J., Chen, Q., Lu, Z., Lu, F., Lin, C., Xia, Z., Yang, Y., Li, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202514486 · Cited by 4
Cancer‐associated fibroblasts mediate resistance to neoadjuvant therapy in breast cancer
Xia, Z., Vermeulen, S., Suwal, U., Rappu, P., Heino, J., Vuyst, F. D., Dedeyne, S., Hendrix, A., Denys, H. G., & Wever, O. D. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1779 · Cited by 2
Gündel, B., Liu, X., Pfützenreuter, A.-M., Engelsberger, V., Weiskirchen, R., Löhr, M. J., & Heuchel, R. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179369 · Cited by 4
“There is abundant evidence that the dense fibrosis in the tumor microenvironment induces both intrinsic and extrinsic gemcitabine resistance [41–45].”
BackgroundNieves, J. G., Nietzer, S., Lechner, L., Weigel, T., Bauer, L., Fuchs, K., Remmert, C., Putz, E., Kuhn, S. P., Hudecek, M., et al. (2025) · Materialia · doi:10.1016/j.mtla.2025.102440 · Cited by 2
Rajbongshi, L., Kim, J., Lee, J.-E., Lee, S.-R., Hwang, S.-Y., Kim, Y., Hong, Y. M., Oh, S., Kim, B. S., Lee, D., et al. (2025) · Marine Drugs · doi:10.3390/md23100386 · Cited by 2
Rational Drug Repurposing Using sscMap Analysis in a HOX-TALE Model of Leukemia
Kettyle, L. M., Liberante, F. G., & Thompson, A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1242-1_21 · Cited by 2
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0024-x · Cited by 5
In vitro three-dimensional modeling for prostate cancer
Dondossola, E., & Paindelli, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818128-7.00012-5 · Cited by 2
Cancer Metastasis - Molecular Mechanism and Clinical Therapy
Tutar, Y., & Tutar, L. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100926 · Cited by 2
Surdez, D., & Daudigeos‐Dubus, E. (2016) · Revue d Oncologie Hématologie Pédiatrique · doi:10.1016/j.oncohp.2016.10.017 · Cited by 2
Patient-Derived Tumor Xenografts in Hematologic Disorders
Pizzi, M., & Inghirami, G. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00022-9 · Cited by 2
Bi, H., Zhang, Z., Guo, L., & Fu, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18791 · Cited by 2
Assessing Specificity of Anticancer Drugs In Vitro
Kluwe, L. (2016) · Journal of Visualized Experiments · doi:10.3791/53752-v · Cited by 6
Shi, L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc271 · Cited by 2
Metadata
- Authors
- McMillin, D. W., Negri, J. M., & Mitsiades, C. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Corresponding author
- Mitsiades, Constantine S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-03
- Volume
- 12
- Issue
- 3
- Pages
- 217-228
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1980669422
- Cited by
- 474
- References
- 150
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 27 · 2023: 34 · 2022: 29 · 2021: 43 · 2020: 41 · 2019: 33 · 2018: 49 · 2017: 56 · 2016: 41 · 2015: 40 · 2014: 27 · 2013: 16
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R0-1 50947)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- tumor microenvironment, stromal cells, drug resistance, drug sensitivity, anticancer drug discovery, preclinical models, orthotopic xenograft, metastasis
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Drug Screening Assays, Antitumor, Humans, Neoplasms, Stromal Cells, Drug Resistance, Neoplasm, Drug Discovery, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.